Healthcare Provider Recommendations and Observed Changes in HPV Vaccination Acceptance during the COVID-19 Pandemic

doi:10.3390/vaccines10091515

. 2022 Sep 12;10(9):1515.

doi: 10.3390/vaccines10091515.

Healthcare Provider Recommendations and Observed Changes in HPV Vaccination Acceptance during the COVID-19 Pandemic

Ikponmwosa Osaghae^{1

2

3}, Onyema Greg Chido-Amajuoyi⁴, Sanjay Shete^{1

2

4}

Affiliations

¹ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center at Houston (UTHealth), School of Public Health, Houston, TX 77030, USA.
⁴ Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

PMID: 36146593
PMCID: PMC9504052
DOI: 10.3390/vaccines10091515

Healthcare Provider Recommendations and Observed Changes in HPV Vaccination Acceptance during the COVID-19 Pandemic

Ikponmwosa Osaghae et al. Vaccines (Basel). 2022.

. 2022 Sep 12;10(9):1515.

doi: 10.3390/vaccines10091515.

Authors

Ikponmwosa Osaghae^{1

2

3}, Onyema Greg Chido-Amajuoyi⁴, Sanjay Shete^{1

2

4}

Affiliations

¹ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center at Houston (UTHealth), School of Public Health, Houston, TX 77030, USA.
⁴ Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

PMID: 36146593
PMCID: PMC9504052
DOI: 10.3390/vaccines10091515

Abstract

Healthcare provider (HCP) recommendation of the human papillomavirus (HPV) vaccination is crucial for HPV vaccination acceptance and uptake. It is unclear to what extent the disruptive effect of the COVID-19 pandemic impacted the recommendation and acceptance of HPV vaccination. HCPs practicing in Texas were invited to complete an online survey between January and April 2021. This population-based survey examined the association between HPV vaccination recommendation by HCPs and their observed changes in HPV vaccination acceptance during the COVID-19 pandemic. Of the total 715 HCPs included in this study, 13.9% reported a decrease, 8.7% reported an increase, and 77.5% reported no change in HPV vaccination acceptance during the COVID-19 pandemic. Compared to the HCPs who never/sometimes recommend HPV vaccination, those who often/always recommend HPV vaccination were less likely to observe a decrease (12.3% vs. 22.1%) and more likely to observe an increase in HPV vaccination (9.1% vs. 6.2%), during the COVID-19 pandemic. Furthermore, those who provided recommendations often/always had 46% (odds ratio: 0.54; 95%CI: 0.30-0.96) lower odds of reporting a decrease in HPV vaccination acceptance during the COVID-19 pandemic. This study adds to prior evidence of the positive influence of provider recommendations on HPV vaccination acceptance despite the disruptive effect of the COVID-19 pandemic on cancer prevention services.

Keywords: COVID-19; HPV vaccination; healthcare provider; provider recommendation; vaccination acceptance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Barriers and Facilitators of Romanian HPV (Human Papillomavirus) Vaccination.
Manolescu LSC, Zugravu C, Zaharia CN, Dumitrescu AI, Prasacu I, Radu MC, Letiția GD, Nita I, Cristache CM, Gales LN. Manolescu LSC, et al. Vaccines (Basel). 2022 Oct 15;10(10):1722. doi: 10.3390/vaccines10101722. Vaccines (Basel). 2022. PMID: 36298587 Free PMC article.
Stakeholders' Perceptions on the Implementation of the HPV Vaccine School-Entry Requirement in Puerto Rico during the COVID-19 Pandemic.
Vázquez-Otero C, Medina-Laabes DT, Pérez-Guzmán D, Díaz-Miranda OL, Mercado-Andino AK, Escabí-Wojna EI, Colón-López V. Vázquez-Otero C, et al. Vaccines (Basel). 2024 Jul 10;12(7):760. doi: 10.3390/vaccines12070760. Vaccines (Basel). 2024. PMID: 39066398 Free PMC article.
Human papillomavirus vaccination status among university students in Southern Thailand: A cross-sectional study.
Sono S, Sukhanonsawat N, Naknuan N, Auttasongkroh P, Suwanno R, Kiratikosol K, Sookpong K, Sukpornsinchai N, Sirikornpinyo L, Nakarae W, Laomanachareon S. Sono S, et al. Prev Med Rep. 2024 Aug 13;46:102857. doi: 10.1016/j.pmedr.2024.102857. eCollection 2024 Oct. Prev Med Rep. 2024. PMID: 39253725 Free PMC article.
Pediatric Oncology Providers' HPV Vaccine Knowledge, Attitude, Self-Efficacy, and Practice after Communication Training: A Comparison with a National Survey.
Teixeira RA, Grimes A, Embry L, Aguilar C, Shay LA. Teixeira RA, et al. Vaccines (Basel). 2024 Sep 17;12(9):1060. doi: 10.3390/vaccines12091060. Vaccines (Basel). 2024. PMID: 39340090 Free PMC article.
Association Between the Information Environment, Knowledge, Perceived Lack of Information, and Uptake of the HPV Vaccine in Female and Male Undergraduate Students in Belgrade, Serbia.
Mandić-Rajčević S, Stojković VJ, Paunić M, Ristić SS, Obradović M, Vuković D, Cvjetković S. Mandić-Rajčević S, et al. Eur J Investig Health Psychol Educ. 2025 Feb 7;15(2):21. doi: 10.3390/ejihpe15020021. Eur J Investig Health Psychol Educ. 2025. PMID: 39997085 Free PMC article.

See all "Cited by" articles

References

1. Meites E., Gee J., Unger E., Unger E., Markowitz L. Human papillomavirus. In: Hamborsky J., editor. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. CDC; Atlanta, GA, USA: 2015. [(accessed on 15 June 2022)]. pp. 175–186. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#hpv.
1. De Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health. 2020;8:e180–e190. doi: 10.1016/S2214-109X(19)30488-7. - DOI - PubMed
1. Chesson H., Dunne E., Hariri S., Markowitz L. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex. Transm. Dis. 2014;41:660–664. doi: 10.1097/OLQ.0000000000000193. - DOI - PMC - PubMed
1. Centers for Disease Control and Prevention Human papillomavirus: HPV Infection. [(accessed on 29 August 2022)]; Available online: https://www.cdc.gov/hpv/parents/about-hpv.html.updated2021.
1. Lei J., Ploner A., Elfström K.M., Wang J., Roth A., Fang F., Sundström K., Dillner J., Sparén P. HPV vaccination and the risk of invasive cervical cancer. N. Engl. J. Med. 2020;383:1340–1348. doi: 10.1056/NEJMoa1917338. - DOI - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Meites E., Gee J., Unger E., Unger E., Markowitz L. Human papillomavirus. In: Hamborsky J., editor. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. CDC; Atlanta, GA, USA: 2015. [(accessed on 15 June 2022)]. pp. 175–186. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#hpv.

[2] Meites E., Gee J., Unger E., Unger E., Markowitz L. Human papillomavirus. In: Hamborsky J., editor. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. CDC; Atlanta, GA, USA: 2015. [(accessed on 15 June 2022)]. pp. 175–186. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#hpv.

[3] De Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health. 2020;8:e180–e190. doi: 10.1016/S2214-109X(19)30488-7. - DOI - PubMed

[4] De Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health. 2020;8:e180–e190. doi: 10.1016/S2214-109X(19)30488-7. - DOI - PubMed

[5] Chesson H., Dunne E., Hariri S., Markowitz L. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex. Transm. Dis. 2014;41:660–664. doi: 10.1097/OLQ.0000000000000193. - DOI - PMC - PubMed

[6] Chesson H., Dunne E., Hariri S., Markowitz L. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex. Transm. Dis. 2014;41:660–664. doi: 10.1097/OLQ.0000000000000193. - DOI - PMC - PubMed

[7] Centers for Disease Control and Prevention Human papillomavirus: HPV Infection. [(accessed on 29 August 2022)]; Available online: https://www.cdc.gov/hpv/parents/about-hpv.html.updated2021.

[8] Centers for Disease Control and Prevention Human papillomavirus: HPV Infection. [(accessed on 29 August 2022)]; Available online: https://www.cdc.gov/hpv/parents/about-hpv.html.updated2021.

[9] Lei J., Ploner A., Elfström K.M., Wang J., Roth A., Fang F., Sundström K., Dillner J., Sparén P. HPV vaccination and the risk of invasive cervical cancer. N. Engl. J. Med. 2020;383:1340–1348. doi: 10.1056/NEJMoa1917338. - DOI - PubMed

[10] Lei J., Ploner A., Elfström K.M., Wang J., Roth A., Fang F., Sundström K., Dillner J., Sparén P. HPV vaccination and the risk of invasive cervical cancer. N. Engl. J. Med. 2020;383:1340–1348. doi: 10.1056/NEJMoa1917338. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Healthcare Provider Recommendations and Observed Changes in HPV Vaccination Acceptance during the COVID-19 Pandemic

Affiliations

Healthcare Provider Recommendations and Observed Changes in HPV Vaccination Acceptance during the COVID-19 Pandemic

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous